top of page
Current Article
  • Writer's pictureLUNAC Therapeutics

LUNAC Therapeutics Shortlisted for Medilink Healthcare Business Award

Leeds, UK, 25 June 2021: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the development of advanced life-saving anticoagulants has been shortlisted for the Start Up award at the 2021 Medilink North of England Healthcare Business Awards.

The Medilink Healthcare Business Awards showcase the best in the Life Sciences sector in this region. The shortlist represents organisations from industry, academia and the NHS from across the North West, North East, Yorkshire and the Humber. This award recognises newly established companies that show a promising future. This year, the winners will be unveiled in a virtual event, taking place on 29 June.

Dr. Mervyn Turner, Chair of LUNAC Therapeutics, commented:

We are delighted that LUNAC has been shortlisted for the upcoming North of England Medilink awards. With our strong academic heritage firmly rooted in the North of England we are excited to be part of this growing and vibrant community. This is another recognition of LUNAC’s potential to transform patients’ lives and is further testament to progress being made by our team to advance our pre-clinical programmes.”

About LUNAC Therapeutics

LUNAC Therapeutics is a spin out from the University of Leeds pursuing the discovery of next generation oral anticoagulant therapies with a reduced risk of causing bleeding compared to current treatments. LUNAC’s primary focus is on the inhibition of activated Factor XII (FXIIa), a clotting factor enzyme which plays a role in pathological clot formation (thrombosis), but not in the stemming of bleeding (haemostasis).

The business is founded on IP generated by Professor Helen Philippou (Professor of Translational Medicine in the Faculty of Medicine and Health at the University of Leeds) and Dr Richard Foster (Associate Professor in the Faculty of Engineering and Physical Sciences at the University of Leeds), built on a decade of academic research into FXIIa in association with some of the world’s leading supporters of scientific and medical research, including the Wellcome Trust, British Heart Foundation and the UK’s Medical Research Council. Investors include Epidarex Capital and Mercia Asset Management PLC. LUNAC was the 2020 Start Up of the Year winner at the BioNow awards and is shortlisted for Best Biotech Start Up Award at the upcoming OBN awards.

For more information, please go to Follow LUNAC on Twitter @LUNACtx1.


bottom of page